Our team is heading to ACTRIMS 2/29-3/2 and we look forward to connecting with you! More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design

Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis

Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis

1 2 8

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design

Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis

Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis